Key result
KardiaMobile 6L nearly doubles detection of clinically significant arrhythmias versus standard ambulatory monitoring.
Why the study?
Comparative effectiveness in detecting clinically significant arrhythmias between standard ambulatory ECG monitoring modalities and 30-day use of the patient-initiated KardiaMobile 6L device was unknown.
Does 30-day symptom-triggered 6-lead ECG monitoring improve the detection of clinically significant arrhythmias compared to standard ambulatory ECG monitoring in patients with unexplained palpitations or dizziness?
Cohort (n=350)
No
Does 30-day symptom-triggered 6-lead ECG monitoring improve the detection of clinically significant arrhythmias compared to standard ambulatory ECG monitoring in patients with unexplained palpitations or dizziness?
A 30-day symptom-triggered 6-lead smartphone ECG monitoring strategy significantly increases the detection of clinically relevant arrhythmias compared to traditional short-duration ambulatory monitoring.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Traditional short-duration monitoring simply misses too many transient events, creating a costly diagnostic blind spot for clinicians. This landmark study from the University of Rochester proves that putting our medical-grade, 6-lead device directly into patients' hands nearly doubles the diagnostic yield. By empowering patients to capture arrhythmias the moment symptoms occur, we can accelerate accurate diagnoses, optimize clinical workflows, and get patients to life-saving treatment faster—ultimately preventing critical cardiac episodes and the compounding costs of undetected conditions.”
“Symptom-triggered ECG recordings obtained over 30 days were superior to standard 24- or 48-hour Holter recordings and to prolonged multiday recordings in detecting clinically significant arrhythmias. KM6L might be considered as the first line of diagnostic process in individuals with uncertain causes of cardiac symptoms.”
Symptom-triggered KardiaMobile monitoring was associated with higher arrhythmia detection; hypothesis-generating and requires randomized trials before changing practice.
BACKGROUND: Patients with palpitations and dizziness are typically monitored using ambulatory electrocardiographic (ECG) monitoring including Holter monitors and extended continuous ECG monitors. The KardiaMobile 6L (KM6L), a portable medical-grade ECG recorder, enables patients to initiate 6-lead ECG recordings during symptoms when needed. OBJECTIVES: This study aimed to assess the comparative effectiveness in detecting clinically significant arrhythmias between ambulatory ECG monitoring modalities and 30-day use of KM6L. METHODS: Patients with palpitations or other arrhythmic symptoms who were referred to for standard ambulatory monitoring (either 24- or 48-hour Holter or ambulatory ECG patch) were asked to perform 1-minute, 6-lead ECG recordings with the KM6L device during symptomatic episodes over a 30-day period. Clinically significant arrhythmias were defined as atrial fibrillation/flutter, second/third-degree atrioventricular block, wide complex tachycardia, supraventricular tachycardia >100 bpm, pauses >3 seconds, or sinus tachycardia >130 bpm. Detection rates between KM6L and standard monitoring were compared using McNemar test. RESULTS: We enrolled 350 (40%, n = 140 with 24/48-hour Holter) patients who recorded 6,251 KM6L recordings (median 15 per patient). Significant arrhythmias were detected in 66 patients (18.9%) using either ambulatory ECG monitoring or KM6L. Ambulatory ECG monitoring modalities identified arrhythmias in 27 patients (7.7%), whereas KM6L detected arrhythmias in 52 patients (14.9%) (P < 0.001). Importantly, 39 arrhythmia episodes (11.1%) were detected exclusively by KM6L (P = 0.0008), most commonly atrial fibrillation (n = 23). CONCLUSIONS: These findings demonstrate that patient-initiated, symptom-triggered ECG monitoring substantially enhances arrhythmia detection compared with traditional short-duration monitoring.
No takes yet. Share an insight, caveat, or question.
Dzikowicz et al. (2026) conducted a cohort in Unexplained palpitations, dizziness, or lightheadedness (n=350). KardiaMobile 6L (KM6L) vs. Standard ambulatory ECG monitoring (24- or 48-hour Holter or extended patch ECG monitor) was evaluated on Detection of clinically significant arrhythmias (p=<0.001). Symptom-triggered 30-day monitoring with the KardiaMobile 6L device significantly increased the detection of clinically significant arrhythmias to 14.9% compared to 7.7% with standard ambulatory monitoring.
Synapse has enriched 10 related papers. Consider them for comparative context: